METHODS OF TREATING PROSTATE CANCER WITH GnRH ANTAGONIST
The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.
1 - 89 . (canceled)
90 . A method of treating advanced stage prostate cancer in a subject, comprising:
administering an initial dose of 240 mg of degarelix to the subject as two injections of 120 mg each, and
administering a maintenance dose of 80 mg of degarelix to the subject as one injection, wherein the maintenance dose is administered approximately every 28 days after the previous dose of degarelix for a duration of treatment,
wherein the treated subject has a decreased likelihood of urinary tract infection during treatment compared to treatment with a gonadotrophin releasing hormone (GnRH) agonist.
91 . The method of claim 90 , wherein the subject has locally advanced stage prostate cancer.
92 . The method of claim 90 , wherein the subject is less than 65 years old.
93 . The method of claim 90 , wherein the initial dose of degarelix is given as two subcutaneous injections of 120 mg each at a concentration of 40 mg/mL.
94 . The method of claim 90 , wherein the maintenance dose of degarelix of 80 mg is given as one subcutaneous injection at a concentration of 20 mg/mL.
95 . The method of claim 90 , wherein the GnRH agonist is leuprolide.
96 . The method of claim 90 , wherein the treatment with a GnRH agonist is treatment with monthly intramuscular injections of 7.5 mg leuprolide.